FDA inspection
Lianyungang Kangle Pharmaceutical Co., Ltd.: FDA inspection ending Sep 19, 2025
FDA inspection 1291764 · Voluntary Action Indicated (VAI) · Lianyungang
Key facts
| Inspection ID | 1291764 |
|---|---|
| Firm | Lianyungang Kangle Pharmaceutical Co., Ltd. |
| FEI number | 3010728729 |
| Address | Ganyu, No. 2 Hua South Rd; Ganyuxian |
| City | Lianyungang |
| Country | China |
| Fiscal year | 2025 |
| Inspection end date | Sep 19, 2025 |
| Classification | Voluntary Action Indicated (VAI) |
| Project area | Drug Quality Assurance |
| Product type | Drugs |
At a glance
- None Citations
- 1–9 Posted citations
- No Warning letter followed
- Yes Form FDA 483 issued
- No Establishment inspection report (EIR) exists
- 1–9 Inspections at this FEI
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA inspections
FDA inspections are classified as No Action Indicated (NAI), Voluntary Action Indicated (VAI) or Official Action Indicated (OAI). Inspections of individual clinical investigators are not published here.
Source: U.S. Food and Drug Administration (FDA), inspection classification data